ArticleFrontiers in molecular biosciences2025
Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Proteomic landscape analysis of undifferentiated pleomorphic sarcoma.Genome medicine · 2026Article
- Current insights into PHF14: molecular features and functional roles.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Undifferentiated spindle cell sarcoma (USCS) is a rare and heterogeneous group without specific diagnostic, prognostic, or predictive markers. The clinicopathologic and proteomic characteristics of USCS remain largely unknown. Methods: Between 2008 and 2024, we collected 14 low-grade USCSs and 104 undifferentiated pleomorphic sarcomas (UPSs). We conducted a comprehensive mass spectrometry (MS) proteomic analysis on USCSs and compared the clinicopathologic characteristics of low-grade USCSs and UPSs. More than 5600 proteins could be identified. Results: Low-grade USCSs had 353 upregulated and 500 downregulated proteins compared to corresponding normal tissue. PHRF1, DIDO1, RAPH1, GGT7, and PHF14 exhibited overexpression in low-grade USCSs, whereas SERPINF2, TMEM40, FYCO1, COL2A1, and NPNT demonstrated low expression. The KEGG pathway enrichment analysis revealed that most of the enriched pathways in low-grade USCS were related to various amino acid and lipid metabolic. Correlating significantly changed proteins with their targeting medications revealed novel therapy options for low-grade USCSs. Furthermore, in comparison to UPSs, our findings indicate that low-grade USCSs may exhibit smaller sizes and a lower rate of distant metastasis. In summary, to the best of our knowledge, this is the first in-depth proteomic analysis to demonstrate a comprehensive investigation of the clinicopathological and proteomic characteristics of low-grade USCSs. Conclusion: We initially elucidated the characteristics of differential proteins, the pathways enriched, and their possible drug targets in low-grade USCSs. Data are available via ProteomeXchange with identifier PXD061644.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.